VOLUME 12 (2021)
Table of Contents
Editorial
|
| Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors |
|
https://doi.org/10.18632/oncotarget.27861
Erika J. Crosby, H. Kim Lyerly, Zachary C. Hartman
|
| 1-3 |
|
| Carving a niche for immunotherapy in ovarian cancer |
|
https://doi.org/10.18632/oncotarget.27864
Nitasha Gupta, Erika Lampert, Jung-Min Lee
|
| 4-7 |
|
| Glioma immunoediting, a driver of tumor evolution, and the next battle for immunotherapy |
|
https://doi.org/10.18632/oncotarget.27865
Adam M. Sonabend, Roger Stupp, Catalina Lee-Chang, Hideho Okada
|
| 8-9 |
Research Perspectives
|
| Combination therapies for MPNSTs targeting RABL6A-RB1 signaling |
|
https://doi.org/10.18632/oncotarget.27862
Jordan L. Kohlmeyer, David J. Gordon, Munir R. Tanas, Rebecca D. Dodd, Varun Monga, Benjamin W. Darbro, Dawn E. Quelle
|
| 10-14 |
Research Papers
|
| Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer |
|
https://doi.org/10.18632/oncotarget.27855
Krastan B. Blagoev, Roumen Iordanov, Mengxi Zhou, Tito Fojo, Susan E. Bates
|
| 15-21 |
|
| Characterization of FGFR signaling in prostate cancer stem cells and inhibition via TKI treatment |
|
https://doi.org/10.18632/oncotarget.27859
Juyeon Ko, April N. Meyer, Martin Haas, Daniel J. Donoghue
|
| 22-36 |
|
| Total lesion glycolysis in oral squamous cell carcinoma as a biomarker derived from pre-operative FDG PET/CT outperforms established prognostic factors in a newly developed multivariate prediction model |
|
https://doi.org/10.18632/oncotarget.27857
Gerrit Spanier, Daniela Weidt, Dirk Hellwig, Johannes K.H. Meier, Torsten E. Reichert, Jirka Grosse
|
| 37-48 |
|
| The noradrenergic profile of plasma metanephrine in neuroblastoma patients is reproduced in xenograft mice models and arise from PNMT downregulation |
|
https://doi.org/10.18632/oncotarget.27858
Karim Abid, Maja Beck Popovic, Katia Balmas Bourloud, Jacqueline Schoumans, Joana Grand-Guillaume, Eric Grouzmann, Annick Mühlethaler-Mottet
|
| 49-60 |
Corrections
|
| Correction: Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals |
|
https://doi.org/10.18632/oncotarget.27638
Pengjun Zhou, Rong Zhang, Ying Wang, Dandan Xu, Li Zhang, Jinhong Qin, Guifeng Su, Yue Feng, Hongce Chen, Siyuan You, Wen Rui, Huizhong Liu, Suhong Chen, Hongyuan Chen, Yifei Wang
|
| 61-62 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
